YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

Inclusion Criteria: * Patient will be a recipient of a primary (first) ABO compatible cadaveric liver allograft * Patient's age is less than 18 years * Patient is not a recipient of a multivisceral transplant or simultaneous kidney transplant * Patient has not undergone prior organ or cellular transplant of any type * Patient has a Model for End Stage Liver Disease (MELD) score of ≤38 * Cold ischemia time (CIT) anticipated to be less than 14 hours * Donor liver procured by UCLA liver team * Veno-veno bypass is not planned to be used for the patient (e.g. no prior surgery or other factor that indicates a risk for excessive blood loss and therefore a need for veno-veno bypass +/- autologous recovery during surgery) * For patients who are women of childbearing potential, patient has a negative pregnancy test (either urine or serum) within 48 hours prior to transplant * Patient (male and female) is willing to use an acceptable form of birth control for at least 3 months post-treatment * Patient is willing and able to sign informed consent. Exclusion Criteria: * Patient has a prior organ transplant of any type * Patient has known allergic or intolerance reactions to human immune globulins, antibodies, or components of the formulation or known contraindication to administration of YSPSL * Patient has an uncontrolled active infection (on antibiotics with controlled infection is not an exclusion) * Patient has active Hepatitis B virus (HBV)/transplant for HBV related cirrhosis * P…